Phase 3 Results for Adjuvant Treatment with Merck’s KEYTRUDA® Show Superior RFS in Patients With Resected High-Risk Stage II Melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced on Saturday the first results from the … Continue reading Phase 3 Results for Adjuvant Treatment with Merck’s KEYTRUDA® Show Superior RFS in Patients With Resected High-Risk Stage II Melanoma

Pharma Industry Review